These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2181432)

  • 1. Effects of antianginal drugs on myocardial energy metabolism in coronary artery disease.
    Bagger JP
    Pharmacol Toxicol; 1990; 66 Suppl 4():1-31. PubMed ID: 2181432
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ischemic myocardial metabolism and antianginal drugs].
    Ichihara K
    Nihon Yakurigaku Zasshi; 1986 Dec; 88(6):403-12. PubMed ID: 3549484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A preclinical evaluation of the antianginal activity of energy metabolism intermediates].
    Kostin VI
    Farmakol Toksikol; 1989; 52(6):49-52. PubMed ID: 2560436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of trimetazidine after acute myocardial infarction.
    Banach M; Rysz J; Goch A; Mikhailidis DP; Rosano GM
    Curr Vasc Pharmacol; 2008 Oct; 6(4):282-91. PubMed ID: 18855716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian patterns of myocardial ischaemia and the effects of antianginal drugs.
    Purcell H; Mulcahy D; Fox K
    Chronobiol Int; 1991; 8(5):309-20. PubMed ID: 1818781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial metabolism and threshold to angina in coronary artery disease after digitalization: responses at rest and during stress.
    Ferlinz J; Siegel J; Van Herick R; Aronow WS
    Am J Med; 1979 Feb; 66(2):288-95. PubMed ID: 425970
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of nifedipine on coronary haemodynamics and myocardial metabolism in coronary artery disease.
    Bagger JP; Nielsen TT
    Eur Heart J; 1985 Jan; 6(1):75-84. PubMed ID: 4006961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-anginal effects of partial fatty acid oxidation inhibitors.
    Lam A; Lopaschuk GD
    Curr Opin Pharmacol; 2007 Apr; 7(2):179-85. PubMed ID: 17307396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of antianginal preparations on the hemodynamics and metabolism of the ischemic myocardium].
    Makolkin VI; Vakhliaev VD
    Eksp Klin Farmakol; 1996; 59(4):18-20. PubMed ID: 9026181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A method for evaluating antianginal drugs in experimental animals: assessment of myocardial ischemia by myocardial pH.
    Abiko Y; Ichihara K; Sakai K; Sashida H; Ishibashi T
    Methods Find Exp Clin Pharmacol; 1986 May; 8(5):271-8. PubMed ID: 2873274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Collateral coronary blood circulation and its role in the mechanism of the anti-ischemic (antianginal) action of pharmacologic preparations].
    Chichkanov GG; Tsorin IB
    Farmakol Toksikol; 1989; 52(2):15-24. PubMed ID: 2663540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs that Affect Cardiac Metabolism: Focus on Perhexiline.
    Chong CR; Sallustio B; Horowitz JD
    Cardiovasc Drugs Ther; 2016 Aug; 30(4):399-405. PubMed ID: 27106834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenous glucose during pacing-induced angina pectoris in patients with coronary artery disease.
    Zir LM; Nocero MM; Rose M; Weisinger B; Krauss K; Glassman E
    Cathet Cardiovasc Diagn; 1976; 2(1):49-57. PubMed ID: 1260850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The cardioprotective action of carnitine and its structural analog 3-(2,2,2-trimethylhydrazine)propionate on cardiac energy metabolism in experimental occlusion of the coronary artery in rats].
    Ratunova TM; Bauman VR; Kalvin'sh IIa
    Farmakol Toksikol; 1989; 52(5):24-7. PubMed ID: 2599072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic management of ischaemic heart disease.
    Chierchia SL; Fragasso G
    Eur Heart J; 1993 Nov; 14 Suppl G():2-5. PubMed ID: 7904560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glycerinated myocardiocyte fibers in the rat myocardium as one of the models in a preclinical assessment of antianginal agents].
    Dzhanpoladian EG; Sambelian VM; Kaĭfadzhian MA; Tatinian NG; Khoetsian EL
    Biull Eksp Biol Med; 1989 Apr; 107(4):444-6. PubMed ID: 2720162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina.
    Deedwania PC; Carbajal EV
    Am J Med; 2011 Aug; 124(8):681-8. PubMed ID: 21787900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of diltiazem in coronary artery disease.
    Kenny J; Daly K; Bergman G; Kerkez S; Jewitt DE
    Br Heart J; 1984 Jul; 52(1):53-6. PubMed ID: 6743423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Agents for the metabolic correction of myocardial energy metabolism in treating patients with ischemic heart disease].
    Vizyr AD; Kraĭdashenko OV; Berezin OIe; Oliĭnyk OI
    Lik Sprava; 2000 Mar; (2):26-30. PubMed ID: 10862469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Angina Pectoris Associated with Coronary Microvascular Dysfunction.
    Ong P; Athanasiadis A; Sechtem U
    Cardiovasc Drugs Ther; 2016 Aug; 30(4):351-356. PubMed ID: 27358172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.